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Background: Liver resections (LRs) are performed with increasing frequency for metastatic disease. To
minimize the risk of postoperative complications, a period of 6 weeks between the last dose of chemo-
therapy and LR is typically recommended. The current study examines postoperative morbidity and
mortality following LR in patients who received chemotherapy within 30 days prior to LR.
Methods: The merged 2005–2007 National Surgical Quality Improvement Program (NSQIP) Participant
Use File was queried for perioperative risk factors, laboratory values and postoperative occurrences
or complications in patients who underwent LR. Patients were grouped according to their receipt or
non-receipt of chemotherapy within 30 days prior to LR and major postoperative complications.
Results: A total of 2331 patients underwent LR; 2147 did not receive chemotherapy within 30 days of
resection (No Chemo group) and 184 received chemotherapy within 30 days prior to resection (Chemo
group). The groups were similar with regard to preoperative co-morbidities and operative factors. The
median NSQIP statistically computed morbidity probability was similar between the groups (No Chemo
0.32, Chemo 0.34; P = 0.07), whereas the median mortality probability was higher in the Chemo group
(0.02) than the No Chemo group (0.014; P = 0.001). Thirty-day survival was similar between the two
groups (No Chemo 97%, Chemo 98%; P = 0.44). Major complication rates did not differ between the
groups (No Chemo 20%, Chemo 18%; P = 0.51). Factors associated with major complications in the
Chemo group included: extent of resection; intraoperative transfusion; preoperative ascites, and pre-
operative haematocrit.
Discussion: Major morbidity was not increased in Chemo patients. The strongest predictors of major
postoperative complications in the Chemo group were extent of resection and intraoperative red cell
transfusion. Although the NSQIP dataset does not include data about tumour type or chemotherapy
regimen, these data suggest that LR may be safely performed within 30 days of chemotherapy, thereby
minimizing the length of time during which patients do not receive systemic treatment.
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Introduction
An increasing number of liver resections (LRs) are being
performed in North America; several groups have reported a 1.5-
to two-fold increase in hepatic resections.1–3 It is likely that this
increase largely reflects a growth in the number of LRs performed
for colorectal hepatic metastases. In an era of highly effective
chemotherapy for metastatic colorectal cancer, more patients are
undergoing LR as part of a multimodal treatment plan designed
to remove all their disease. Modern series of LRs for colorectal
hepatic metastases indicate that the majority of patients receive
systemic chemotherapy prior to LR.2,4,5
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Surgeons who perform LRs in patients following systemic
therapy have reported both gross and histological changes in the
liver parenchyma.6–8 Several investigators have sought to deter-
mine whether these phenotypic changes are associated with a
change in postoperative complications. Three recent studies have
examined the impact of preoperative chemotherapy on postop-
erative complications following LR for colorectal metastases.4,9,10
None of these studies found an increase in postoperative compli-
cations following preoperative chemotherapy. By contrast with
these studies, reports by Karoui et al.6 and Konopke et al.11 found
a greater than two-fold increase in postoperative complications
in patients who received chemotherapy prior to LR.
Currently, there is no consensus regarding the risk of post-
operative complications following use of systemic chemotherapy
prior to major LR. Significant contributors to the conflicting
findings cited include the retrospective nature of the majority
of studies on this topic and a lack of standardized assessment of
postoperative complications. We sought to address these two
major limitations by using data available from a multi-institution
database in which both preoperative co-morbidities and postop-
erative complications are evaluated and recorded according to a
carefully prescribed protocol. The American College of Surgeons
National Surgical Quality Improvement Program (ACS-NSQIP)
database was queried for postoperative complications following
major LR. We compared postoperative morbidity and mortality
in patients who did and did not receive systemic chemotherapy
within 30 days of LR. The aims of the current study were: (i) to
assess the potential impact of preoperative chemotherapy within
30 days of major LR on postoperative complications and mortal-
ity, and (ii) to identify patients at increased risk for postoperative
complications following major LR and to determine if there




The ACS-NSQIP methodologies have been described
previously.12–16 Briefly, data were submitted to the ACS-NSQIP
by 121 hospitals in 2005–2006. A total of 152 490 general and
vascular surgery cases were included in the 2005–2006 dataset.
Data were submitted by 183 hospitals in 2007, yielding a total of
211 407 cases. The data from the 2005–2006 and 2007 Participant
Use Files were merged to produce a combined dataset incorporat-
ing all submitted cases over the 2005–2007 period. Each hospital
utilizes a clinical nurse reviewer to collect preoperative patient
characteristics, including risk factors, intraoperative variables
and postoperative adverse occurrences (complications) that occur
within 30 days following the surgical procedure. Cases submitted
by each participating institution include the first 40 eligible
general and vascular surgery cases performed in an 8-day cycle,
with each 8-day cycle starting on a different day of the week. All
clinical nurse reviewers have completed an in-depth training
course on all study definitions. Data reliability is assured through
periodic site visits by external nurse reviewers to confirm inter-
rater reliability of captured data points. Outcomes for each case
are determined on postoperative day 30 through nurse chart
review, reports from morbidity and mortality conferences, and
communication with each patient via letter or telephone call.
Description of data subsets and variables used
in the current study
Of the 363 897 cases in the merged 2005–2007 ACS-NSQIP data-
base, 2331 cases were identified as involving a major open LR
based upon the following principal Current Procedural Termi-
nology (CPT) codes: 47120 (partial lobectomy, n = 1357); 47122
(trisegmentectomy, n = 230); 47125 (left hepatectomy, n = 232),
and 47130 (right hepatectomy, n = 512). The analysis was limited
to major open LRs because of the appreciable morbidity asso-
ciated with partial lobectomy to extended hepatectomy
(18–30%10,17) and because modern series of colorectal hepatic
metastasectomies involve multisegment resections.2,10,18
Patients were then separated into two groups based upon their
receipt or non-receipt of chemotherapy within 30 days of LR (No
Chemo and Chemo groups). According to the ACS-NSQIP defi-
nition, patients were identified as having received chemotherapy if
they ‘had any chemotherapy treatment for cancer in the 30 days
prior to surgery’. Chemotherapy included, but was not limited to,
oral and parenteral chemotherapy agents. If treatment consisted
solely of hormonal therapy, the patient was not considered to
have received chemotherapy. The ACS-NSQIP database does not
include any information about the specific type of chemotherapy
received within 30 days prior to operation, the number of cycles of
chemotherapy received, or the precise interval within the 30-day
timeframe between the last dose of chemotherapy and the LR.
Neither does the database indicate the histological type of malig-
nancy for which the therapy was received. Patients in the No
Chemo group included any patient who underwent a major open
LE (as defined above) but did not receive chemotherapy within 30
days of resection. The indication for hepatectomy is not specified
in the ACS-NSQIP database.
The preoperative variables collected for the ACS-NSQIP
describe patient demographic characteristics and co-morbidities.
The preoperative variables specifically analysed in the current
study included: age; gender; race; current smoking history;
current alcohol use; body mass index (BMI); American Society of
Anesthesiologists (ASA) physical status classification; presence of
diabetes mellitus; history of severe chronic obstructive pulmonary
disease; ascites; congestive heart failure within 30 days of surgery;
hypertension requiring medication; disseminated cancer; steroid
use for chronic conditions; loss of >10% of body weight in the
previous 6 months; transfusion of >4 units of packed red blood
cells (pRBC) within the preoperative 72 h, and radiation therapy
for malignancy within 90 days of operation. According to the
ACS-NSQIP database protocol, a patient was considered to have
disseminated cancer if it had ‘spread to one site or more sites in
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addition to the primary site’ or if ‘the presence of multiple
metastases indicates the cancer is widespread, fulminant or near
terminal’.
Ten preoperative laboratory values were examined: creatinine;
albumin; serum glutamic oxaloacetic transaminase (SGOT); total
bilirubin; alkaline phosphatase; white blood cell count (WBC);
haematocrit; platelet count; partial thromboplastin time (PTT),
and prothrombin time (PT). Absolute values were converted into
normal and abnormal values based upon the following institu-
tional reference ranges: creatinine 0.5–1.5 mg/dl; albumin 3.5–
5.0 g/dl; SGOT 0–75 U/l; total bilirubin 0.1–1.2 mg/dl; alkaline
phosphatase 25–165 U/l; WBC 4.5–11.0 k/ml; haematocrit
36–50%; platelet count 140–415 k/ml; PTT 0–36 s, and PT 0–15 s.
Operative variables analysed included the extent of LR, total
operative time, and administration of pRBC transfusion. Partial
hepatectomy was defined as CPT code 47120 and extensive hepa-
tectomy as CPT codes 47122, 47125 or 47130.
Postoperative occurrences were assessed up to 30 days post-
operatively, and included both in-hospital and out-of-hospital
occurrences. Postoperative infectious occurrences included: super-
ficial incisional infection; deep incisional infection; organ space
infection; pneumonia; urinary tract infection (UTI); sepsis, and
septic shock. The following pulmonary occurrences were analysed:
unplanned intubation; need for ventilatory assistance >48 h post-
operatively; pneumonia, and pulmonary embolism. Cardiac
occurrences included: myocardial infarction, and cardiac arrest
requiring cardiopulmonary resuscitation (CPR). Deep venous
thrombosis and pulmonary embolism were recorded as throm-
boembolic occurrences. Additional occurrences noted included
wound disruption, transfusion of pRBC within 72 h post-
operatively, and return to the operating room within 30 days
postoperatively.
The occurrence of any one of the following complications was
classified as a minor complication: superficial incisional infection;
deep wound infection; wound disruption, or UTI.
The occurrence of any one of the following complications was
classified as a major complication: organ space infection; pneumo-
nia; unplanned intubation; pulmonary embolism; ventilatory
support >48 h; progressive renal insufficiency; acute renal failure;
stroke; coma for >24 h; cardiac arrest requiring CPR; myocardial
infarction; deep venous thrombosis; sepsis; septic shock, and
return to the operating room within 30 days postoperatively.
Patients were grouped according to their receipt or non-receipt
of chemotherapy within 30 days prior to LR and the occurrence or
absence of a major postoperative complication.
Morbidity and mortality probability calculations
Risk-adjusted 30-day postoperative mortality and morbidity were
calculated for each hospital by logistic regression analysis with
30-day postoperative mortality and morbidity as dependent vari-
ables and patient preoperative and perioperative risk factors as
independent variables. Regression analyses included patients from
all hospitals participating in the ACS-NSQIP. A mortality and
morbidity probability was calculated for each patient and then
summed to obtain an expected number of deaths or patients with
complications for each hospital.
Statistical analysis
Student’s t-test with equal variances was used for comparison of
continuous variables and Pearson’s chi-squared and Fisher’s exact
test were used for analysis of discrete variables. A stepwise forward
logistic regression was used for multivariate model determination.
The variables were retained if they significantly contributed to the
model (P < 0.15) in the presence of other variables, as determined
by the likelihood ratio test. Differences of P < 0.05 were considered
significant. All analyses were performed using spss Version 17.0
(SPSS, Inc., Chicago, IL, USA).
Results
Demographics and co-morbidities by
chemotherapy group
The merged 2005–2007 ACS-NSQIP database contained a total of
2331 open major LRs. Of these, 2147 resections (92%) were per-
formed in patients who had not received chemotherapy within 30
days of resection and 184 (8%) were performed in patients within
30 days of administration of chemotherapy. The demographics
and co-morbidities of patients in the No Chemo and Chemo
groups are summarized in Table 1. The average age in both groups
was approximately 58 years. There were more men in the Chemo
than the No Chemo group. The majority of patients in both
groups were White, non-smokers, non-drinkers, had an average
BMI of 27 and belonged to ASA classes 2 or 3. The two groups of
patients were also well matched for co-morbidities, including dia-
betes mellitus, history of severe chronic obstructive pulmonary
disease, congestive heart failure, hypertension, loss of >10% of
body weight over the previous 6 months, steroid use and ascites.
Significantly more patients in the Chemo group had disseminated
cancer and had received radiotherapy for malignancy in the 90
days prior to LR.
Operative variables by chemotherapy group
An analysis of the operative variables revealed no differences in
the extent of LR, total operative time, or units of pRBC received
intraoperatively between patients who did and did not receive
chemotherapy within 30 days of LR (Table 2). Slightly more than
half the patients in both groups underwent a partial lobectomy,
and the remainder of the patients underwent a hemihepatectomy
or trisegmentectomy. Median operative time was a median of
21 min longer in the Chemo group. The median number of pRBC
received intraoperatively was zero in both groups.
Morbidity and mortality probability and postoperative
occurrences by chemotherapy group
The median values for ACS-NSQIP statistically computed mor-
bidity probability were similar in both groups (No Chemo 0.32,
Chemo 0.34; P = 0.07). This indicates that the risk-adjusted
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30-day frequency of postoperative occurrences was predicted to
be similar between the two groups based upon a statistical model
that included patient preoperative risk factors as independent
variables and individual hospital risk-adjusted 30-day postopera-
tive morbidity as the dependent variable. The median mortality
probability was higher in the Chemo group (0.02) compared with
the No Chemo group (0.01; P = 0.001), indicating a higher pre-
dicted mortality among patients undergoing LR following pre-
operative chemotherapy.
Minor complications occurred in 10% of patients in the
No Chemo group and 12% of patients in the Chemo group
(P = non-significant [NS]). Major complications occurred in 20%
of patients in the No Chemo group and 18% of patients in the
Chemo group (P = NS). The frequencies of wound-related, infec-
tious,pulmonary, cardiac, thromboembolic, and overall minor and
major complications in the Chemo and No Chemo groups are
illustrated in Table 3. There was no difference in the occurrence of
any of the infection-related complications between the two groups.
The need for an unplanned intubation was more common in the
No Chemo group (84/2147, 4%) compared with the Chemo group
(2/184, 1%;P = 0.05). Cardiac and thromboembolic complications
were similarly uncommon in both groups. In both groups, 1% of
Table 1 Demographics and co-morbidities of patients who did and did not receive chemotherapy within 30 days of liver resection
No chemotherapy Chemotherapy P-value
n = 2147 (%) n = 184 (%)
Age, years 58.4  13.7 57.3  10.6 0.30
Men 1045 (49) 104 (57) 0.04
Race 0.40
Indian/Alaskan 9 (0.4) 1 (0.5)
Asian 89 (4) 5 (3)
Black/Black Hispanic 170 (8) 10 (5)
Hispanic/Hispanic unknown 73 (3) 2 (1)
White 1650 (77) 156 (85)
Unknown 156 (7) 10 (5)
Current smoker 328 (15) 28 (15) 0.98
>2 alcoholic drinks/day 61 (3) 6 (3) 0.74
Body mass index, median 26.9 27.2 0.15
ASA physical status classification 0.72
1 35 (1.6) 3 (1.6)
2 729 (34) 58 (31.5)
3 1272 (59) 117 (64)
4 110 (0.5) 6 (3)
5 1 (0.04) 0 (0)
Co-morbidities
Diabetes mellitus 0.07
No 1825 (85) 168 (91)
Oral hypoglycaemic treatment 228 (11) 11 (6)
Insulin therapy 94 (4) 5 (3)
History of severe chronic obstructive pulmonary disease 67 (3) 3 (2) 0.26
Congestive heart failure within the 30 days prior to surgery 8 (0.4) 1 (0.5) 0.72
Hypertension requiring medication 988 (46) 74 (40) 0.13
Loss of >10% of body weight in previous 6 months 114 (5) 12 (6.5) 0.49
Transfusion >5 units pRBC preoperatively 6 (0.3) 1 (0.5) 0.44
Steroid use for chronic condition 40 (2) 4 (2) 0.77
Ascites 31 (1) 2 (1) 0.69
Disseminated cancer 818 (38) 147 (77) <0.001
Radiotherapy for malignancy in last 90 days 16 (0.7) 11 (6) <0.001
ASA, American Society of Anesthesiologists; pRBC, packed red blood cells
P-values shown in bold are significant at P < 0.05
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patients required a pRBC transfusion in the 72 h following LR.
Approximately 5% of patients in both groups required a return to
the operating room within 30 days of the initial LR. Thirty-day
survival was similar between the two groups: 97% of patients in the
No Chemo group and 98% of patients in the Chemo group were
alive at 30 days post-surgery (P = 0.44)
Univariate correlates of major postoperative
complications: all subjects
Patients were separated into two groups based upon the occur-
rence of a major postoperative complication (e.g. pulmonary
embolism, sepsis, need for re-intubation) (Table 4). The following
demographic and co-morbidities were more common among
patients with major complications: older age; male gender;
current smoking history; higher ASA class; history of severe
chronic obstructive pulmonary disease; loss of >10% of body
weight in the previous 6 months, and ascites. Neither dissemi-
nated cancer nor the receipt of radiotherapy for malignancy
within 90 days prior to LR were associated with developing a
major postoperative complication. Patients who developed a
major complication were more likely to have abnormal laboratory
values for all of the variables examined than patients without a
Table 2 Operative variables in patients who did and did not receive chemotherapy within the 30 days prior to liver resection
No chemotherapy Chemotherapy P-value
n = 2147 (%) n = 184 (%)
Extent of liver resection 0.99
Partial lobectomy 1250 (58) 107 (58)
Hemihepatectomy/trisegmentectomy 897 (42) 77 (42)
Total operative time, min 251.7  122.5 267.7  119.1 0.09
Median, min 229 250
Units of pRBC given intraoperatively 0.9  5.6 1.3  3.8 0.30
Median 0 0
pRBC, packed red blood cells
Table 3 Postoperative occurrences in patients who did and did not receive chemotherapy within the 30 days prior to liver resection
No chemotherapy Chemotherapy P-value
n = 2147 (%) n = 184 (%)
Minor complications 224 (10) 22 (12) 0.52
Major complications 432 (20) 33 (18) 0.56
Infectious complications
Superficial incisional infection 110 (5) 14 (8) 0.15
Deep incisional infection 23 (1) 0 0.16
Organ space infection 133 (6) 6 (3) 0.11
Pneumonia 86 (4) 7 (4) 0.89
Urinary tract infection 19 (1) 7 (4) 0.78
Sepsis 149 (7) 6 (3) 0.06
Septic shock 77 (4) 10 (5) 0.20
Pulmonary complications
Unplanned intubation 84 (4) 2 (1) 0.05
Ventilatory assistance >48 h 101 (5) 5 (3) 0.21
Wound disruption 19 (1) 2 (1) 0.78
Cardiac complications
Myocardial infarction 8 (0.4) 0 0.41
Cardiac arrest requiring cardiopulmonary resuscitation 24 (1) 1 (0.5) 0.47
Thromboembolic events
Deep venous thrombosis 44 (2) 5 (3) 0.54
Pulmonary embolism 33 (1.5) 5 (3) 0.23
Transfusion of red blood cells within 72 h postoperatively 22 (1) 2 (1) 0.94
Return to operating room within 30 days 105 (5) 11 (6) 0.52
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Table 4 (A) Univariate correlates of major postoperative complications following liver resection in all subjects. (B) Univariate correlates of
major postoperative complication following liver resection in the chemotherapy group
(A) No complications Major complications P-value
n = 1866 (%) n = 465 (%)
Age, years 58.0  13.6 59.5  13.1 0.03
Age 65 years 632 (34) 182 (39) 0.03
Men 882 (46) 267 (57) <0.001
Race 0.53
Indian/Alaskan 7 (0.4) 3 (0.6)
Asian 77 (4) 17 (4)
Black/Black Hispanic 140 (7) 40 (9)
Hispanic/Hispanic unknown 58 (3) 17 (4)
White 1441 (77) 365 (78.5)
Unknown 143 (8) 23 (5)
Current smoker 260 (14) 96 (21) <0.001
>2 alcoholic drinks/day 52 (3) 15 (3) 0.64
Body mass index, median 26.9 27.1 0.73
ASA physical status classification <0.001
1 33 (2) 5 (1)
2 664 (36) 23 (26.5)
3 1099 (59) 290 (62)
4 70 (4) 46 (10)
5 0 1 (0.2)
Co-morbidities
Diabetes mellitus 0.24
No 1606 (86) 387 (83)
Oral hypoglycaemic treatment 186 (10) 53 (11)
Insulin therapy 74 (4) 25 (5)
History of severe chronic obstructive pulmonary disease 40 (2) 30 (6.5) <0.001
Congestive heart failure within 30 days before surgery 6 (0.3) 3 (0.6) 0.40
Hypertension requiring medication 839 (45) 223 (48) 0.25
Loss of >10% of body weight in previous 6 months 89 (5) 37 (8) 0.008
Transfusion >4 units pRBC preoperatively 5 (0.3) 2 (0.4) 0.63
Steroid use for chronic condition 31 (2) 13 (3) 0.13
Ascites 17 (1) 16 (3) <0.001
Disseminated cancer 776 (42) 184 (40) 0.46
Chemotherapy 151 (8) 33 (7) 0.56
Radiotherapy for malignancy in last 90 days 24 (1) 3 (0.6) 0.34
Preoperative laboratory variables n/% abnormal n/% abnormal
Creatinine 75 (4) 33 (7) 0.009
Albumin 169 (10.5) 83 (20) <0.001
Total bilirubin 82 (5) 43 (10) <0.001
SGOT 125 (8) 56 (14) <0.001
Alkaline phosphatase 216 (13) 112 (27) <0.001
White blood cell 126 (7) 58 (13) <0.001
Haematocrit 317 (17.5) 121 (27) <0.001
Platelets 138 (7.6) 52 (11.5) 0.01
Partial thromboplastin time 67 (5) 31 (8) 0.02
Prothrombin time 63 (4) 34 (9) 0.001
Operative variables
Extent of liver resection <0.001
Partial lobectomy 1138 (61) 219 (47)
Hemihepatectomy/trisegmentectomy 728 (39) 246 (53)
Operative length, min 238.3  111.4 311.8  6.6 <0.001
Unites of pRBC given intraoperatively 0.6  5.1 2.2  6.6
Median 0 0 <0.001
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major complication. The most common laboratory abnormalities
in the complication group were an elevated alkaline phosphatase
and a low haematocrit (27%), followed by a low albumin (20%).
Subjects who developed a major complication were more likely to
have undergone an extensive LR. The average operative time was
longer among subjects who developed a major complication and
the number of pRBC received intraoperatively was an average of
four-fold higher.
Univariate correlates of major postoperative
complications: Chemo group
In order to determine which variables may uniquely predict the
risk of a major complication among patients in the Chemo group,
we separately examined the relationship between the preoperative
variables and major postoperative complications in this group.
Major complications occurred in 33 (18%) of patients in the
Chemo group. Complications were associated with the following
preoperative factors: higher ASA class; congestive heart failure
within 30 days preoperatively; transfusion of >4 units preopera-
tively, and presence of ascites. Of these four variables, preoperative
congestive heart failure and transfusion were unique risk factors
for postoperative complications in the Chemo group. The true
impact of congestive heart failure and preoperative transfusions
on major complication rates in the Chemo group is uncertain,
given that the difference between the No Chemo and Chemo
groups reflects the fact that a single patient in the Chemo group
had each of these risk factors. Patients who developed a major
complication were more likely to have abnormal creatinine, SGOT
and haematocrit values compared with those who did not develop
a complication. The most common laboratory abnormality was
a low haematocrit (41%).
When more stringent criteria were used to determine the
impact of neutropenia (WBC count5.0 k/ml, n = 692), anaemia
(haematocrit 24%, n = 13) and thrombocytopenia (platelet
Table 4 Continued
(B) No complications Major complications P-value
n = 151 (%) n = 33 (%)
ASA physical status classification 0.05
1 3 (2) 0
2 52 (34) 6 (18)
3 93 (62) 24 (73)
4 3 (2) 3 (9)
5 0 0
Co-morbidities
Congestive heart failure within 30 days before surgery 0 1 (3) 0.03
Transfusion >4 units pRBC preoperatively 0 1 (3) 0.03
Ascites 0 2 (6) 0.002
Preoperative laboratory variables N/% abnormal N/% abnormal
Creatinine 2 (1) 3 (9) 0.04
Albumin 11 (8) 6 (19) 0.09
Total bilirubin 3 (2) 3 (10) 0.08
SGOT 3 (2) 4 (13) 0.02
Alkaline phosphatase 13 (10) 5 (16) 0.33
White blood cell 16 (11) 7 (22) 0.14
Haematocrit 30 (20) 13 (41) 0.02
Platelets 18 (12) 6 (19) 0.39
Partial thromboplastin time 4 (3.5) 3 (11.5) 0.12
Prothrombin time 2 (2) 2 (7) 0.16
Operative variables
Extent of liver resection 0.02
Partial lobectomy 94 (62) 13 (39)
Hemihepatectomy/trisegmentectomy 57 (38) 20 (61)
Operative length, min 254.9  108.4 326.1  147.8 0.002
Units of pRBC given intraoperatively 0.8  2.1 3.7  7.5 <0.001
ASA, American Society of Anesthesiologists; pRBC, packed red blood cells; SGOT, serum glutamic oxaloacetic transaminase
P-values shown in bold are significant at P < 0.05
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count 100 k/ml, n = 61) on major postoperative complications,
thrombocytopenia, but not neutropenia, was associated with a
higher rate of complications. A total of 23 (38%) patients with
thrombocytopenia developed a major complication compared
with 428 (19.5%) patients with platelet counts >100 k/ml (P =
0.001). A total of 18% of patients with neutropenia developed
complications compared with 21% of patients with WBC
>5.0 k/ml (P = 0.17). No analysis was performed for anaemia
because only a small number of patients met the criteria for this
complication.
Similar to findings for the group as a whole, subgroup results
showed that patients who received preoperative chemotherapy
and developed a postoperative complication were more likely to
have undergone extensive LRs, had longer operative times and
received more units of pRBC intraoperatively.
Multivariate predictors of major postoperative
complications
Clinical variables from the univariate analysis of postoperative
complications with a P-value < 0.15 were entered into a binary
logistic regression analysis to identify independent predictors of
postoperative complications. These variables included: age <65 or
65 years; gender; current smoker; ASA class 1–2 or 3–5; history
of severe chronic obstructive pulmonary disease; loss of >10%
of body weight in the previous 6 months; ascites; extent of LR
(partial or extensive); steroid use for a chronic condition, and
receipt of pRBC intraoperatively. Independent predictors of a
major postoperative complication following LR are summarized
in Table 5 and include: gender; history of severe chronic obstruc-
tive pulmonary disease; ascites; extent of LR, and receipt of pRBC
intraoperatively. We were unable to perform multivariate analysis
separately for patients in the Chemo group because of the
small number of patients in this group who developed a major
complication.
Discussion
Contemporary series of LRs for colorectal metastases reveal that
the majority of patients currently receive systemic chemotherapy
prior to resection.2,4,5 Although surgeons and pathologists have
noted morphological and histopathological liver changes induced
by preoperative chemotherapy, it is unclear if these changes are
associated with a difference in postoperative morbidity following
LR. Some authors have reported no increase in postoperative mor-
bidity in LRs performed following systemic chemotherapy,4,9,10
whereas other investigators have recorded an increase in post-
operative complications.6,11
To evaluate the impact of chemotherapy prior to LR on
postoperative complications and mortality, we interrogated the
ACS-NSQIP database for major LRs performed in the presence or
absence of preoperative chemotherapy. A total of 2331 major LRs
were included in the merged 2005–2007 ACS-NSQIP database. Of
these, 8% (n = 184) were performed in patients who had received
systemic chemotherapy within 30 days of resection. The two
groups were similar with regard to age, ethnicity, and preoperative
co-morbidities. Minor complications occurred in 10% of patients
in the No Chemo group and 12% of patients in the Chemo group.
Major complications occurred at a similar rate in the two groups:
20% in the No Chemo group and 18% in the Chemo group. There
were no differences between the Chemo and No Chemo groups
for any of the specific infection-related, pulmonary, wound-
related, cardiac or thromboembolic occurrences analysed. The
results of the current study confirm those of several other authors
who did not demonstrate an increase in postoperative morbidity
in patients who received chemotherapy prior to major LR.4,5,7,9,10,19
The 30-day mortality in the current study was 2–3% and did
not differ between the Chemo and No Chemo groups. Vauthey
et al.10 reported an overall 90-day mortality of 2.7% in their study
of 406 patients who underwent resection for colorectal hepatic
metastases (248 received preoperative chemotherapy). They chose
to report 90-day mortality in order to account for the deaths that
can occur late in the postoperative course following hepatic resec-
tion as a result of progressive liver failure secondary to impaired
hepatic regeneration. It is possible that the 30-day mortality value
in the current study is an underestimate of overall postoperative
mortality, given this possibility of late liver failure.
In addition to confirming a lack of increased morbidity
following preoperative chemotherapy prior to LR, the results of
the current study provide insight into a safe therapeutic window
between systemic chemotherapy and LR. Because the ACS-NSQIP
database specifically defines preoperative chemotherapy as
therapy given within 30 days of the principal procedure, we may
conclude that major LR can be safely performed within this
timeframe. Traditionally, surgeons and oncologists have waited a





Age 1.14 0.91–1.43 0.26
Male gender 1.4 1.13–1.74 0.002
ASA class 1.21 0.95–1.54 0.12
Diabetes mellitus 1.09 0.81–1.47 0.57
History of chronic obstructive
pulmonary disease
2.8 1.7–4.7 <0.001
Loss of >10% of body weight
in previous 6 months
1.4 0.91–2.13 0.12
Ascites 2.9 1.4–5.9 0.004
Steroid use for chronic condition 1.3 0.64–2.6 0.48
Extent of liver resection 0.65 0.52–0.80 <0.001
Intraoperative pRBC transfusion 2.6 2.1–3.2 <0.001
95% CI, 95% confidence interval; ASA, American Society of Anesthe-
siologists; pRBC, packed red blood cells
P-values shown in bold are significant at P < 0.05
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minimum of 6 weeks between the last administration of chemo-
therapy and a major surgical procedure in order to minimize the
risk of postoperative complications. The current data suggest that
LR may be safely performed within 30 days of systemic chemo-
therapy without increasing the risk of minor or major postopera-
tive complications or 30-day mortality. Minimizing the interval
between receipt of systemic chemotherapy and LR is desirable
because this will result in at least a theoretical reduction in the
time during which a patient is at risk of disease progression while
between therapies (surgery and chemotherapy).
Several caveats must be considered when applying the results
of the current study to a specific clinical scenario, however. The
ACS-NSQIP database does not record the type of chemotherapy
received, the number of cycles received, the precise interval
(within the 30-day timeframe) between the last dose of chemo-
therapy and the LR, or the malignancy for which the chemo-
therapy was given. Consequently, there may be specific
chemotherapeutic agents for which a longer delay (>30 days)
between receipt of chemotherapy and LR is warranted. A recent
study by Welsh et al.18 found that neither the interval (in weeks)
between finishing chemotherapy and undergoing LR nor the
duration of chemotherapy (in months) impacted postoperative
morbidity. However, they did note a reduction in complications
with increasing time between the completion of chemotherapy
and LR. Additionally, although it is likely that the majority of LRs
performed following chemotherapy in the current study were per-
formed for colorectal metastases (the most common metastatic
liver tumour resected in the USA), this cannot be definitively
determined in the current dataset. As a result, we are unable to
make specific recommendations about LRs performed for a given
tumour type.
The second aim of our study was to identify patients at
increased risk for postoperative complications following major
LR, and to determine if there are risk factors specific to patients
who receive preoperative chemotherapy. For the group as a whole,
major complications occurred more often in older patients (65
years), men, current smokers, patients with a higher ASA class,
patients with a history of severe chronic obstructive pulmonary
disease, patients who had lost >10% of their body weight in the
6 months prior to surgery, and those with preoperative ascites.
Major complications in the Chemo group were associated with
higher ASA class, congestive heart failure within the 30 days prior
to surgery, transfusion of >4 units preoperatively, and preopera-
tive ascites. Of these four preoperative variables, only preoperative
congestive heart failure and preoperative transfusion were unique
risk factors among patients who received preoperative chemo-
therapy. However, the differences between the No Chemo and
Chemo groups were accounted for by a single patient with preop-
erative congestive heart failure and a single patient who received
>4 units of pRBC preoperatively in the Chemo group. Conse-
quently, we were not able to identify any preoperative risk factors
for major postoperative complications unique to patients in the
Chemo group.
Patients who developed major complications were more likely
to have abnormal values for all of the laboratory studies examined
than patients without a major postoperative complication. The
most common laboratory abnormalities were elevated alkaline
phosphatase and low haematocrit (27%). Using more stringent
criteria to define neutropenia and thrombocytopenia, we found
that major complications were more common in patients with
thrombocytopenia, but not in those with neutropenia.
In an earlier review of postoperative morbidity following LR
by the Patient Safety in Surgery Study group,20 elevated alkaline
phosphatase, but not low haematocrit, was associated with post-
operative complications. Of the three laboratory abnormalities
that differed between subjects in the Chemo group with and
without a major complication, the most common abnormality in
the complication group was low haematocrit (41%). Our findings
are in contrast to those of Melis et al.,21 who reported that preop-
erative anaemia was not associated with an increased risk of post-
operative complications following oesophagectomy. However,
they did find that anaemic patients were more likely to receive a
pRBC transfusion, which itself was an independent predictor of
postoperative complications.21 Given that major complications
were more common among Chemo patients who were anaemic
and among those who required >4 units of pRBC preoperatively,
these may represent a group of patients who warrant additional
attention prior to undertaking major hepatectomy in order
to minimize postoperative morbidity. There may also be an
increased risk for postoperative complications in LR patients with
thrombocytopenia as this may be an indicator of portal hyperten-
sion and/or bone marrow suppression.
All three intraoperative variables examined (extent of LR,
operative length, units of pRBC received intraoperatively) corre-
lated with the risk of a major postoperative morbidity for the
group overall as well as the Chemo group alone. Our results are in
agreement with those of several other groups who found these
three factors to be associated with an increased risk of com-
plications following LR.6,22,23 Konopke et al.11 also reported that
transfusion of 3–6 pRBC units was significantly associated with
postoperative morbidity and temporary liver failure. Blood trans-
fusions have been shown to increase morbidity in a variety
of patient populations, including those undergoing colorectal,
vascular and thoracic procedures.24–26
The results of our multivariate analysis revealed five factors
independently associated with a major postoperative compli-
cation following hepatectomy: male gender; history of chronic
obstructive pulmonary disease; preoperative ascites; extent of LR,
and intraoperative pRBC transfusion. The correlation between
extent of LR and perioperative blood transfusions on post-
operative morbidity following LR has been discussed above.
Recognition of male gender as an independent risk factor for
postoperative complications following hepatic resection was
previously reported by Fong et al.27 and was noted in a study of
postoperative complications following LR by Virani et al.,20 but
was not seen in the study by Karoui et al.6 Neither ascites nor a
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history of chronic obstructive pulmonary disease were found to
be associated with postoperative morbidity following LR in the
study by Virani et al.20
At least two significant limitations of the ACS-NSQIP data-
base should be noted. The first is the absence of procedure- or
specialty-specific complications. For example, incidences of post-
operative bile leak and liver failure are not captured in the data-
base. Additionally, ACS-NSQIP does not grade the severity of
complications recorded. The importance of this additional layer
of analysis is illustrated in the studies by Scoggins et al.5 and
Sahajpal et al.9 The complication grading scale used by Scoggins
et al.5 classified complications according to the intervention
required to manage them (e.g. local wound care, interventional
radiology, drainage, etc.). The Clavien Scale28 was employed in the
study by Sahajpal et al.9 They found that the majority of compli-
cations in their chemotherapy group were Clavien grade IIa, indi-
cating ‘potentially life-threatening complications with the need
for intervention and prolonged hospital stay, requiring medical
intervention only’. Patients in their No Chemo group were equally
likely to have a Clavien grade I or IIa complication, suggesting
that the severity of postoperative complications may be lower in
patients who do not receive chemotherapy prior to LR.
This analysis reveals that hepatic resection can be safely per-
formed in patients who receive chemotherapy during the 30 days
prior to resection and that 30-day mortality and morbidity rates are
comparable with those for patients who do not receive preoperative
chemotherapy. Despite higher predicted mortality rates, patients
who received chemotherapy had equivalent 30-day operative mor-
tality. These observations suggest that a predetermined fixed recov-
ery interval between chemotherapy and hepatic resection may not
be required. We conclude that the timing of surgery should be
based on individual patient characteristics with attention to the
recovery of marrow suppression and restoration of red cell mass
and the magnitude of the anticipated hepatic resection. Further,
this study confirms that optimal outcomes are dependent upon
intraoperative measures to minimize blood loss and the need for
transfusions, principles that are linked to improved outcomes in all
major elective and emergent abdominal procedures.
ACS-NSQIP data disclaimer
The American College of Surgeons National Surgical Quality
Improvement Program and the hospitals participating in the
ACS-NSQIP are the source of the data used herein; they have not
verified and are not responsible for the statistical validity of the
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